|
|
|
 |
| Near-Infrared Aggregation-Induced Emission Luminogens for In Vivo Theranostics of Alzheimer’s Disease |
| T. Zhang,# X. Chen,# C. Yuan, X. Pang, Shangguan P., Y. Liu, L. Han, J. Sun, J. W. Y. Lam, Y. Liu, J. Wang,* B. Shi,* B. Z. Tang.* Angew. Chem. Int. Ed. 2022, e202211550. (IF=16.823) |
 |
| Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition |
| M. Ismail,# W. Yang,# Y. Li,# Y. Wang, W. He, J. Wang, P. Muhammad, T. B. Chaston, F. U. Rehman, M. Zheng, D. B. Lovejoy,* B. Shi.* Biomaterials 2022, 289, 121760 (IF=15.305) |
 |
| Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy |
| W. Ruan,# M.Jiao,# S. Xu,# M. Ismail, X. Xie, Y. An, H. Guo, R. Qian,* B. Shi,* M. Zheng.* Journal of Controlled Release 2022, 351, 739–751 (IF=11.467) |
 |
| Arsenic Prodrug-Mediated Tumor Microenvironment Modulation Platform for Synergetic Glioblastoma Therapy |
| J. Yan,# S. Hanif,# D. Zhang, M. Ismail, X. Wang, Q. Li, B. Shi, P. Muhammad,* H. Wu.* ACS Applied Materials & Interfaces 2022, 14, 32, 36487–36502 (IF=10.383) |
 |
| Brain Codelivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy |
| Y. Zou,# Y. Wang,# S. Xu, Y. Liu, J. Yin, D. B. Lovejoy, M. Zheng, X-J Liang, J. B. Park, Y. M. Efremov, I. Ulasovand, B. Shi.* Advanced Materials 2022, 34, 2203958 (IF=32.085) |
 |
| Carbon dots supported single Fe atom nanozyme for drug-resistant glioblastoma therapy by activating autophagy-lysosome pathway |
| P. Muhammad,# S. Hanif,# J. Li, A. Guller, F. U. Rehman, M. Ismail, D. Zhang, X. Yan,* K. Fan,* B. Shi.* Nano Today 2022, 45, 101530 (IF=18.962) |
 |
| Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma |
| M. Ismail,# W. Yang,# Y. Li, T. Chai, D. Zhang, Q. Du, P. Muhammad, S. Hanif, M. Zheng,* B. Shi.* Biomaterials 2022, 287, 121608. (IF=15.305) |
 |
| Blood-brain barrier–penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy |
| Y. Zou,# X. Sun,# Q. Yang, M. Zheng,* O. Shimoni, W. Ruan, Y. Wang, D. Zhang, J. Yin, X. Huang, W. Tao, J. B. Park, X-J Liang, K. W. Leong, B. Shi.* Science Advances 2022, 8, eabm8011.（IF=14.98） |
 |
| Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy |
| M. Zheng,# C. Yan,# Q. Yang, F. Zhu, Q. Du, X. Xia, M. Morsch, A. Lee, J. Yin, Y. Zou, B. Shi.* ChemPhysMater 2022, 1, 203–210. |
 |
| Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy |
| F. U. Rehman,# Y. Liu,# Q. Yang#, H. Yang, R. Liu, D. Zhang, P. Muhammad, Y. Liu, S. Hanif, M. Ismail, M. Zheng,* B. Shi.* Journal of Controlled Release 2022, 345,696–708.（IF=11.467） |
 |
| Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl‑1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy |
| W. He, X. Li, M. Morsch, M. Ismail, Y. Liu, F. U. Rehman, D. Zhang, Y. Wang, M. Zheng, R. Chung, Y. Zou,* and B. Shi.* ACS Nano 2022, 16, 6293−6308. （IF=18.028） |
 |
|
|
